New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional) | PAS 18 730

Opportunity Information: Apply for PAS 18 730

The New Directions in Hematology Research (SHINE-II) funding opportunity (PAS 18-730) is an NIH R01 program designed to jump-start innovative, nonmalignant hematology research that can push the field in genuinely new directions. It is jointly supported by three NIH institutes: the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA). The basic idea is to strengthen and expand the overall nonmalignant hematology research landscape by encouraging projects that test bold, emerging concepts rather than extending well-established lines of work.

A key feature of SHINE-II is that it is intentionally proof-of-principle in nature. Applicants are expected to propose a project that is tightly focused around one specific, central aim. Instead of a multi-aim, sprawling R01 with several parallel objectives, this FOA favors a sharply defined question that can decisively validate a novel concept, method, or approach. The expectation is that a successful SHINE-II project will open new avenues for future discovery, potentially creating the foundation for larger and more comprehensive follow-on studies. Reflecting that goal, projects should be shorter and more limited in scope than a standard R01, with an anticipated project period of about 1 to 3 years.

The announcement is labeled “Clinical Trial Optional,” meaning clinical trials are permitted but not required; applicants can propose either clinical or non-clinical research as long as it fits the nonmalignant hematology mission and the proof-of-principle, single-aim structure. The activity is funded as a grant under an R01 mechanism, within NIH’s broad health-related research area (CFDA numbers listed include 93.839, 93.847, and 93.866). The opportunity is categorized as discretionary federal funding through the National Institutes of Health.

Eligibility is broad and includes many types of domestic U.S. organizations. Examples listed include state, county, city, and township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly highlights additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as eligible federal agencies and faith-based or community-based organizations, regional organizations, and U.S. territories or possessions.

At the same time, there are important limits on foreign participation. Non-domestic (non-U.S.) entities (foreign organizations/institutions) are not eligible to apply directly, and non-domestic components of U.S. organizations are also not eligible to apply. However, “foreign components” as defined by the NIH Grants Policy Statement are allowed, which typically means a U.S. applicant organization may include certain well-justified international elements within an otherwise eligible U.S.-led application, consistent with NIH policy.

From a budgeting standpoint, the source data lists an award ceiling of $200,000 (as provided in the opportunity summary). The record shows an original closing date of 2021-05-07, with a creation date of 2018-03-29, indicating the FOA was originally released in 2018 and had deadlines culminating in 2021 in the provided listing. Overall, SHINE-II is best understood as a targeted NIH R01 pathway for investigators who have a high-upside idea in nonmalignant hematology and can design a focused, time-limited study that credibly demonstrates feasibility or validates a transformative concept.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.839, 93.847, 93.866.
• This funding opportunity was created on 2018-03-29.
• Applicants must submit their applications by 2021-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $200,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAS 18 730

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: